{"schema":"https://ver.cy/schemas/card/1.0.0","id":"vr.tr.isavuconazole","code":"thing-q6079042","url":"https://ver.cy/models/thing/q6079042/","name":"isavuconazole","alternateNames":[],"kind":"thing","status":"published","version":"0.1.0-research.1","language":"en","classifiers":{"family":"Thing Registry","category":"Physical world and living systems","entryKind":"thing","plane":"PHY","domain":["PHY.MAT"],"industry":[],"navPath":"","tags":[],"facets":{}},"whatItIs":"Isavuconazole is a fluorinated triazole antifungal compound that inhibits fungal lanosterol 14α-demethylase, disrupting ergosterol synthesis, and is the active moiety delivered clinically by the prodrug isavuconazonium sulfate.","purpose":"Enable an agent to identify isavuconazole, assess the identity and fitness of a material or measurement, and determine which handling, analytical or pharmacological decisions its evidence supports.","scope":{"in":["Chemical identity, stereochemistry and independently verified substance identifiers","Isavuconazole sample composition, purity, impurities and material form","Condition-dependent physical properties, stability and laboratory handling","Analytical identification and quantification in material and biological matrices","Antifungal activity, resistance and exposure relationships with their evidence limits","Relations to its prodrug, medicinal products and applicable substance requirements"],"out":["The independent chemical identity and manufacturing specification of isavuconazonium sulfate","Finished medicinal product formulations, packaging and administration instructions","Patient-specific prescribing, dosing and treatment decisions","Fungal species taxonomy and complete infection models","Manufacturing plant operations and synthesis process models"],"boundaries":[]},"distinguishingFeatures":["Verify molecular connectivity and stereochemistry against an authenticated isavuconazole reference; an azole-class label alone does not establish identity.","Distinguish measured isavuconazole from isavuconazonium and its sulfate salt rather than treating the names as synonyms.","Determine whether a reported mass denotes actual isavuconazole or an isavuconazole-equivalent amount of prodrug.","Separate an isolated isavuconazole sample from a medicinal product whose label refers to the active moiety.","Require analyte-selective evidence that separates isavuconazole from related substances and degradation products."],"structure":{"bundles":[{"id":"isavuconazole-identity","name":"Isavuconazole identity","description":"Establish which molecular entity the registry entry and each associated record denote.","layers":[{"id":"structure-and-identifiers","name":"Structure and identifiers","description":"Anchor names and database records to the same stereochemically specified substance.","findings":[{"id":"identity-anchor","name":"Structure-backed identity","description":"Require agreement between the reference structure, stereochemistry and identifier records before consolidating substance data.","questions":[{"text":"Which authoritative record establishes the molecular structure and stereochemistry of isavuconazole?","id":"identity-anchor-q01","kind":"definition"},{"text":"Which CAS, PubChem and applicable EC identifiers resolve to that exact entity rather than its prodrug?","id":"identity-anchor-q02","kind":"provenance"}]}]},{"id":"prodrug-and-product-boundaries","name":"Prodrug and product boundaries","description":"Maintain explicit relations between the active substance and records that refer to it indirectly.","findings":[{"id":"active-moiety-accounting","name":"Active-moiety accounting","description":"Distinguish substance identity from active-moiety equivalence in labels and measurements.","questions":[{"text":"Does the record denote isavuconazole itself, isavuconazonium, isavuconazonium sulfate or a formulated product?","id":"active-moiety-accounting-q01","kind":"boundary"},{"text":"If an amount is expressed as isavuconazole equivalents, which documented conversion and rounding convention apply?","id":"active-moiety-accounting-q02","kind":"measurement"}]}]}]},{"id":"material-quality-and-form","name":"Material quality and form","description":"Describe the actual isavuconazole material available for analysis or experimentation.","layers":[{"id":"sample-composition","name":"Sample composition","description":"Qualify the amount of isavuconazole and other components in a specific sample.","findings":[{"id":"assay-and-impurity-basis","name":"Assay and impurity basis","description":"Keep quantitative assay, related substances, water and residual solvents distinguishable.","questions":[{"text":"What is the measured isavuconazole content, and is it reported on an as-is, dried or solvent-free basis?","id":"assay-and-impurity-basis-q01","kind":"measurement"},{"text":"Which methods distinguish stereochemical impurities, other related substances and residual components?","id":"assay-and-impurity-basis-q02","kind":"measurement"},{"text":"Which certificate and acceptance criteria support this sample's intended use?","id":"assay-and-impurity-basis-q03","kind":"provenance"}]}]},{"id":"phase-and-physical-properties","name":"Phase and physical properties","description":"Tie measured constants to the material form and experimental conditions.","findings":[{"id":"condition-qualified-properties","name":"Condition-qualified properties","description":"Record solubility and thermal behaviour without assuming that product or prodrug values describe isavuconazole.","questions":[{"text":"What evidence establishes the sample's phase, solid form and any solvent or water association?","id":"condition-qualified-properties-q01","kind":"measurement"},{"text":"What solubility is measured at the stated solvent composition, pH and temperature?","id":"condition-qualified-properties-q02","kind":"measurement"},{"text":"Do reported thermal values represent melting, decomposition or another transition, and is a boiling point experimentally meaningful?","id":"condition-qualified-properties-q03","kind":"boundary"}]}]}]},{"id":"analytical-recognition","name":"Analytical recognition","description":"Identify and quantify isavuconazole with methods appropriate to the specimen.","layers":[{"id":"selectivity-and-reference-materials","name":"Selectivity and reference materials","description":"Establish that an analytical signal belongs to isavuconazole.","findings":[{"id":"analyte-confirmation","name":"Analyte confirmation","description":"Require reference traceability and demonstrated discrimination from plausible interferents.","questions":[{"text":"Which authenticated reference material anchors chromatographic, spectrometric or structural identification?","id":"analyte-confirmation-q01","kind":"provenance"},{"text":"Can the method distinguish isavuconazole from prodrug, degradation products and matrix interferents?","id":"analyte-confirmation-q02","kind":"measurement"}]}]},{"id":"quantification-and-specimen-integrity","name":"Quantification and specimen integrity","description":"Qualify measured concentrations through calibration and specimen handling.","findings":[{"id":"interpretable-concentration","name":"Interpretable concentration","description":"Attach matrix, analyte basis and validation limits to every concentration result.","questions":[{"text":"Which matrix, units and total or unbound analyte basis define this concentration?","id":"interpretable-concentration-q01","kind":"measurement"},{"text":"What calibration range, uncertainty and quantification limit support the reported value?","id":"interpretable-concentration-q02","kind":"measurement"},{"text":"Could sample handling, instability or prodrug conversion after collection change the measured isavuconazole concentration?","id":"interpretable-concentration-q03","kind":"boundary"}]}]}]},{"id":"antifungal-action-and-exposure","name":"Antifungal action and exposure","description":"Organize evidence connecting isavuconazole exposure to fungal effects.","layers":[{"id":"mechanism-and-susceptibility","name":"Mechanism and susceptibility","description":"Separate molecular mechanism evidence from isolate-level susceptibility observations.","findings":[{"id":"activity-evidence","name":"Activity evidence","description":"Make mechanism, organism coverage and resistance claims traceable to their experimental basis.","questions":[{"text":"Which primary evidence establishes the fungal target and downstream effects of isavuconazole?","id":"activity-evidence-q01","kind":"provenance"},{"text":"For which species and isolates was activity measured, using which susceptibility method and endpoint?","id":"activity-evidence-q02","kind":"measurement"},{"text":"Which resistance mechanisms or cross-resistance findings limit extrapolation from other azoles?","id":"activity-evidence-q03","kind":"boundary"}]}]},{"id":"exposure-and-disposition","name":"Exposure and disposition","description":"Describe pharmacological relationships without turning a substance model into a prescribing protocol.","findings":[{"id":"exposure-interpretation","name":"Exposure interpretation","description":"Qualify disposition and exposure-effect evidence by species, population, sampling and study conditions.","questions":[{"text":"Which studies establish protein binding, metabolism and elimination of measured isavuconazole?","id":"exposure-interpretation-q01","kind":"provenance"},{"text":"Which exposure measures correlate with antifungal effects, and in what experimental or clinical context?","id":"exposure-interpretation-q02","kind":"measurement"},{"text":"When must a concentration interpretation be handed to a patient-specific treatment model?","id":"exposure-interpretation-q03","kind":"action"}]}]}]},{"id":"stewardship-and-use-constraints","name":"Stewardship and use constraints","description":"Determine whether an isavuconazole sample can be handled, retained or used under documented conditions.","layers":[{"id":"storage-and-laboratory-handling","name":"Storage and laboratory handling","description":"Connect sample form and use to stability evidence and applicable hazard information.","findings":[{"id":"qualified-handling","name":"Qualified handling","description":"Require substance-specific support for storage, solution lifetime and protective controls.","questions":[{"text":"Which storage and solution-use conditions have been demonstrated for this isavuconazole material?","id":"qualified-handling-q01","kind":"provenance"},{"text":"Which current SDS, GHS classification and established exposure limits apply to the supplied form?","id":"qualified-handling-q02","kind":"provenance"},{"text":"After a storage excursion or suspected degradation, which reassessment determines whether the sample can be used?","id":"qualified-handling-q03","kind":"action"}]}]},{"id":"biological-and-regulatory-applicability","name":"Biological and regulatory applicability","description":"Preserve the boundaries around safety evidence and permitted uses.","findings":[{"id":"use-evidence-boundaries","name":"Use evidence boundaries","description":"Attach safety and regulatory claims to the studied entity, context and jurisdiction.","questions":[{"text":"Which evidence concerning cardiac repolarization, hepatic effects and drug interactions is attributable to isavuconazole exposure?","id":"use-evidence-boundaries-q01","kind":"provenance"},{"text":"Does a cited authorization or restriction apply to isolated isavuconazole, its prodrug or a particular medicinal product?","id":"use-evidence-boundaries-q02","kind":"boundary"},{"text":"What evidence is required before this specific sample may serve as a reference standard or experimental reagent?","id":"use-evidence-boundaries-q03","kind":"action"}]}]}]},{"id":"evidence-and-external-alignment","name":"Evidence and external alignment","description":"What the world already says about this thing, gathered so the model can be checked against it.","layers":[{"id":"reported-evidence","name":"Reported evidence","description":"Findings from the breadth pass, kept separate from the structural claims.","findings":[{"id":"evidence-confidence-notes","name":"Check these first","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these check these first hold for the sense of isavuconazole this model covers, and on what evidence?","id":"evidence-confidence-notes-q01","kind":"provenance"}]},{"id":"evidence-identifiers","name":"Identifiers and schemes","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these identifiers and schemes hold for the sense of isavuconazole this model covers, and on what evidence?","id":"evidence-identifiers-q01","kind":"provenance"}]},{"id":"evidence-standards-and-regulation","name":"Standards and regulation","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these standards and regulation hold for the sense of isavuconazole this model covers, and on what evidence?","id":"evidence-standards-and-regulation-q01","kind":"provenance"}]},{"id":"evidence-real-world-use","name":"Real-world use","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these real-world use hold for the sense of isavuconazole this model covers, and on what evidence?","id":"evidence-real-world-use-q01","kind":"provenance"}]},{"id":"evidence-measurements","name":"Typical measurements","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these typical measurements hold for the sense of isavuconazole this model covers, and on what evidence?","id":"evidence-measurements-q01","kind":"provenance"}]},{"id":"evidence-failure-modes-and-hazards","name":"Failure modes and hazards","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these failure modes and hazards hold for the sense of isavuconazole this model covers, and on what evidence?","id":"evidence-failure-modes-and-hazards-q01","kind":"provenance"}]},{"id":"evidence-regional-variation","name":"Regional variation","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these regional variation hold for the sense of isavuconazole this model covers, and on what evidence?","id":"evidence-regional-variation-q01","kind":"provenance"}]},{"id":"evidence-neighbours","name":"Neighbouring kinds and how to tell them apart","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these neighbouring kinds and how to tell them apart hold for the sense of isavuconazole this model covers, and on what evidence?","id":"evidence-neighbours-q01","kind":"provenance"}]}]}]}]},"agentConduct":{"may":["Identify isavuconazole by name, identifiers and documented properties, citing sources.","Report approved uses and interactions from regulator-approved product information.","Check a lot's certificate of analysis against its specification for its handler."],"mustNot":["Recommend a dose or a change of antifungal treatment for a particular patient.","Supply or sell it outside lawful pharmaceutical channels.","Release a lot that has failed its specification or lacks a certificate.","Present it as a treatment for an infection it has not been approved for."],"requiresHuman":["Any decision to start, stop or change a patient's antifungal therapy.","Releasing or destroying a material lot."]},"ethics":{"considerations":["Invasive fungal infections are often fatal in vulnerable patients, so errors in supply or advice cost lives.","Antifungal resistance makes careless use a public harm."],"affectedParties":["Patients with invasive fungal infections","Prescribers and pharmacists","Manufacturing staff"]},"owners":{"steward":"The marketing authorization holder for each medicine; the national medicines regulator oversees it.","roles":[],"masterSystems":["National medicines registers"]},"relations":[{"target":"Q11173","type":"parent","note":"registry parent class"}],"interaction":{"identity":{"applicability":"required","items":["Vercy registry: vr.tr.isavuconazole","Wikidata: Q6079042 (https://www.wikidata.org/wiki/Q6079042)"]},"properties":{"applicability":"required","items":["Chemical identity and stereochemical match: Confirmed match | provisional match | mismatch | unresolved; reference structure and identifier authority","Relationship to supplied substance: Isolated substance | active moiety of prodrug | analyte in mixture | reference standard","Assay and reporting basis: % mass fraction or mg/g; as-is, dried or other explicitly defined basis","Related substances and residual components: % or ppm by named impurity; water and residual solvents separately reported","Physical form and phase: Observed phase; crystalline, amorphous or unresolved solid form; solvent or hydrate status where established","Solubility under stated conditions: mg/mL or mol/L with solvent, pH, temperature and equilibration method","Stability and storage qualification: Within qualified conditions | excursion pending assessment | degraded | unknown","Matrix-specific isavuconazole concentration: ng/mL or mg/L; matrix, collection time and total or unbound basis required","Antifungal susceptibility result: MIC in mg/L with organism, isolate, method, endpoint and interpretive standard version","Hazard and regulatory evidence: Substance-specific SDS or authority record with jurisdiction, revision date and applicability"]},"recognition":{"applicability":"required","items":["Identity rests on the label, batch record and certificate of analysis, not appearance.","Clinical products usually carry the prodrug name rather than isavuconazole itself."]},"capabilities":{"applicability":"required","items":["Resolve a substance record to isavuconazole using structure and identifier evidence.","Accept, quarantine or reject a sample against a stated analytical-use specification.","Select an evidence-supported solvent, preparation procedure and storage condition for a defined experiment.","Normalize mass or concentration reports after establishing analyte identity and reporting basis.","Compare antifungal measurements only when organism and assay conditions support comparison.","Route clinical interpretation and product administration questions to linked models with the relevant evidence."]},"hazards":{"applicability":"required","items":["Drug interactions through liver enzymes can raise or lower levels of other medicines.","Confusing the active moiety and the prodrug can lead to dosing errors.","Liver injury and other adverse reactions require clinical monitoring."]},"interfaces":{"applicability":"required","items":["ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, International Council for Harmonisation."]},"context":{"applicability":"required","items":["Isavuconazole is encountered in pharmaceutical analysis and antifungal research as the active compound delivered clinically through the prodrug isavuconazonium sulfate.","Laboratories measure it in biological samples and study its activity against fungi.","Its identity must be distinguished from that of the prodrug when interpreting analytical results or pharmaceutical documentation."]}},"sources":[{"title":"Wikidata item Q6079042: isavuconazole","url":"https://www.wikidata.org/wiki/Q6079042","note":"identity and sense of the item"},{"title":"Wikipedia: Isavuconazonium","url":"https://en.wikipedia.org/wiki/Isavuconazonium","note":"general description of the item"}],"openQuestions":["Which authoritative structure and identifier records establish the exact isavuconazole entity, including stereochemistry and applicable CAS, PubChem and EC identifiers?","Which primary measurements establish solid form, solubility and thermal behaviour for isolated isavuconazole rather than its prodrug or formulated products?","What impurity specifications, stability data and reference-material qualifications are available for the intended sample grade?","Which current susceptibility standards support organism-specific interpretation, and where do breakpoints or exposure targets remain unestablished?","Which substance-specific hazard classifications, exposure limits and jurisdictional restrictions are documented, and which remain unavailable?"],"resources":{"spec":"/models/things/publications/thing-q6079042/spec.json"},"provenance":{"origin":"thing registry research (pass 2)","builtFrom":["models/things/publications/thing-q6079042/spec.json"],"providers":["Codex"],"researchStatus":"unreviewed","generatedAt":"2026-09-12T10:35:23Z","builder":"tools/build_cards.py@1.0.0"},"completeness":{"sections":{"classifiers":"filled","whatItIs":"filled","purpose":"filled","distinguishingFeatures":"filled","structure":"filled","agentConduct":"filled","ethics":"filled","owners":"filled","relations":"filled","interaction.identity":"filled","interaction.properties":"filled","interaction.recognition":"filled","interaction.capabilities":"filled","interaction.hazards":"filled","interaction.interfaces":"filled","interaction.context":"filled","sources":"filled"},"notes":{"_gate":"Published through the thing publication gate 1.0 on 2026-10-07T10:10:32+00:00: completeness 1.00; sense: Wikidata description; 2 live sources; review by codex: pass"},"score":1.0}}